Skip to content

Fontan Physiology Ventilation Strategy

Impact of Fontan Ventilation Strategy on Cardiac Output: An Invasive Physiologic Cross-over Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04672538
Enrollment
32
Registered
2020-12-17
Start date
2021-03-02
Completion date
2023-05-15
Last updated
2023-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Congenital Heart Disease

Brief summary

This study will investigate the different tidal volume (Vt) strategies during a cardiac catheterization procedure to determine whether or not low or high Vt have an impact on cardiac output. Research question: While maintaining the same minute ventilation/PaCO2, does higher Vt (10 cc/kg)/lower rate vs. lower Vt (6 cc/kg)/higher rate (maintaining consistent PEEP) result in improved cardiac output?

Detailed description

The trial will be a randomized crossover design. The study cohort will be randomized (50/50) to begin with either low Vt or high Vt ventilation. After achieving steady state, initial cardiac output measurements will be made using a measured oxygen consumption (VO2) and the Fick principle, per routine clinical protocol. Following baseline assessment of cardiac output and hemodynamics (which is standard of care for all catheterization procedures), participants will be transitioned to the alternative ventilation modality (high Vt or low Vt). After a 5-minute equilibration period, oxygen saturations and VO2 measurements will be re-acquired, to determine cardiac output and hemodynamics in this second state.

Interventions

PROCEDURELow Vt protocol

Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2

PROCEDUREHigh Vt protocol

High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Masking description

Randomized cross over

Intervention model description

The trial will be a randomized crossover design.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients of UPMC Children's Hospital of Pittsburgh that have Fontan physiology (single heart ventricle) that are presenting as outpatients to undergo a cardiac catheterization with general endotracheal anesthesia for purpose of diagnosis or interventional cath. * Parents and/or guardians willing to provide informed consent.

Exclusion criteria

* Those unwilling to give consent and those patients who do not have Fontan physiology. * Any urgent/emergent catheterization procedure will be excluded. * Any Fontan patient having a cardiac catheterization under monitored anesthesia care (as opposed to general endotracheal anesthesia) will not be eligible. * Inability to undergo cardiac catheterization. * Pregnant women will be excluded. * \< 6 weeks post-op from Fontan completion surgery * Same hospitalization as Fontan completion surgery * Intrinsic pulmonary disease which would be anticipated to impact study protocol / findings * Fontan completion surgery performed at age \> 7 years

Design outcomes

Primary

MeasureTime frameDescription
Cardiac OutputMeasurements will occur at the 5-minute equilibration period into the ventilation strategy.The investigators will assess cardiac output using the Fink principle for each arm of randomization.

Secondary

MeasureTime frameDescription
Pulmonary blood flowMeasurements will occur at the 5-minute equilibration period into the ventilation strategy.The investigators will compare blood flow in both arms.
Systemic blood pressureMeasurements will occur at the 5-minute equilibration period into the ventilation strategy.The investigators will assess the vital sign in both intervention arms.
Pulmonary arterial pressureMeasurements will occur at the 5-minute equilibration period into the ventilation strategy.The investigators will assess pressures in both intervention arms.
Pulmonary vascular resistanceMeasurements will occur at the 5-minute equilibration period into the ventilation strategy.Completed using pulmonary vascular resistance (PVR) equation from measurements obtained during the cardiac catheterization.
Systemic vascular resistanceMeasurements will occur at the 5-minute equilibration period into the ventilation strategy.This will be calculated using appropriate equations using measurement obtained during catheterization procedure.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026